← Leaderboards
Ralf Kittler
Ut Southwestern Medical Center
$2,730,611
Attributed
$4,162,532
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,162,532 · 3
By mechanism
R01$4,162,532 · 3
Top collaborators
- Esra Akbay3 shared
- Anthony J Davis3 shared
- John V. Heymach1 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Anthony J Davis$3,457,151
- Chaitanya Suresh Nirodi$1,287,462
- Yang Xie$9,444,566
- Ram Madabhushi$4,869,789
- Hesham Sadek$14,660,558
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsGenesResponseProteinsTumorToxic EffectSpecificityUnited StatesCessation Of LifeCellsMolecular Targeted TherapiesIn VivoNovel Therapeutic InterventionAffectTargeted TreatmentDesignTargeted AgentPreclinical TestingCell LinePre-Clinical ModelRefractoryCancer TherapyClinical TrialsDeubiquitination
Grant awards (9)
Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer$695,004
R01 · FY2025 · CA
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC$551,399
R01 · FY2025 · CA · contact PI
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC$523,830
R01 · FY2024 · CA · contact PI
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC$551,399
R01 · FY2023 · CA · contact PI
Development of small molecules for ERG ablation in prostate cancer$370,575
R01 · FY2020 · CA · contact PI
Development of small molecules for ERG ablation in prostate cancer$359,457
R01 · FY2019 · CA · contact PI
Development of small molecules for ERG ablation in prostate cancer$370,575
R01 · FY2018 · CA · contact PI
Development of small molecules for ERG ablation in prostate cancer$370,575
R01 · FY2017 · CA · contact PI
Development of small molecules for ERG ablation in prostate cancer$369,718
R01 · FY2016 · CA · contact PI